Seven AIDS patients who were receiving suppressive therapy for previously diagnosed cytomegalovirus (CMV) retinitis were offered treatment with protease inhibitors (PIs). Secondary prophylaxis for CMV was discontinued after 3 months of therapy with PIs if patients had ú150 CD4 cells/mm 3 and a human immunodeficiency virus (HIV) load of õ200 copies/mL and if they were negative for CMV as determined by qualitative CMV polymerase chain reaction (PCR). Ophthalmologic exams were done periodically. After a median follow-up of 9 months (range, 9 -12), no new episodes of CMV retinitis were observed. CD4 cell counts were ú150 cells/mm 3 in all cases, HIV loads were õ200 copies/mL, and results for qualitative CMV PCRs remained negative. These observations suggest that for selected patients with healed CMV retinitis who have immunologic and virologic evidence of a clinical response to potent combination antiretroviral therapy, temporary discontinuation of a chronic anti-CMV suppressive therapy may not result in further retinal necrosis. However, the long-term immunologic benefit of PIs and hence the safety of prolonged withdrawal of anti-CMV therapy is unknown.
Cytomegalovirus (CMV) is a common opportunistic infecopment of further clinical events and death in a group of patients with advanced HIV infection [9, 10] . In addition, other tion among AIDS patients, with its incidence increasing with the severity of immunodeficiency. At least 20% of patients studies [11] have shown the immunologic and virologic benefit of antiretroviral therapy (ARVT) that includes PIs. However, with CD4 lymphocyte counts of õ100 cells/mm 3 will develop CMV-related disease over a 2-year period [1] . Retinitis is the important issues about the functional impact of the increase in CD4 cell counts are now being investigated. Connors et al. most common manifestation of CMV disease in human immunodeficiency virus (HIV) -infected patients, and intravenous or [12] have demonstrated that there is a decline in naive CD4 / T cells during the course of HIV infection and that highly oral maintenance therapy is required to avoid or delay progression to retinal destruction and complete vision loss [1] . Howactive antiretroviral therapy (HAART) cannot always restore the number of naive CD4 / T cells even when a dramatic inever, maintenance therapy is associated with a poor quality of life; morbidity, mainly related to catheter complications; and crease in the absolute CD4 / T cell count is achieved. On the other hand, Autran et al. [13] have shown that immunologic a high prevalence of adverse side effects [2, 3] .
Data from observational studies suggest that newer methods reconstitution may be achieved after prolonged viral suppression. Whitcup et al. [14] reported a series of 4 patients who for detection of CMV viremia, such as polymerase chain reaction (PCR) and the detection of pp56 antigenemia in peripheral were followed a median of 6 months (range, 4 -12) without recurrence of CMV after initiating ARVT with PIs. blood polymorphonuclear leukocytes, could have a role for the early diagnosis of CMV disease [4, 5] . Although it has not
The improved knowledge about the natural history of CMV disease and about the immunologic and virologic events folbeen validated in prospective trials, CMV PCR appears to be the best technique for selecting HIV-positive patients suitable lowing ARVT that includes PIs prompted us to discontinue secondary prophylaxis for CMV retinitis after having initiated for primary prophylactic treatment (or preemptive therapy) and also for monitoring maintenance therapy with oral or intrave-ARVT combined with PIs in 7 patients with advanced AIDS. nous ganciclovir and foscarnet [6] [7] [8] .
Several clinical end-point studies with protease inhibitors Patients and Methods (PIs) demonstrated a significant delay in the short-term devel-A cohort of 16 AIDS patients on CMV secondary prophylaxis because of previously diagnosed CMV retinitis were offered HAART. Three of the 16 patients could not adhere to the new This study focusses on the remaining 7 patients who consented lowing combinations: 3TC-stavudine (d4T)-ritonavir (4 patients), 3TC-d4T-ritonavir-saquinavir (2 patients), and 3TC-d4T-indinavir to discontinue secondary prophylaxis. The patients included 6 men and 1 woman with a median age of 33 years (range, 30-43).
(1 patient). At the onset of CMV retinitis and every 3 months after the Their risk behaviors for HIV infection were as follows: 5 were homosexual, 1 had been an injection drug user, and 1 was a blood change in ARVT, we determined the HIV load for each patient by use of a reverse transcription-PCR (Amplicor Roche, Madrid) recipient. All 7 patients presented a first AIDS-defining event prior to the diagnosis of CMV retinitis, with a median interval of 28 with a level of detection of 200 copies/mL. In addition, qualitative plasma CMV PCR was done as described [5] at the diagnosis of months between the two events. The characteristics of the 7 patients at the time of the diagnosis of CMV retinitis and during CMV retinitis, once the patient achieved a CD4 cell count ú150/ mm 3 after changing ARVT, and at 3, 6, and 9 months after disconmaintenance therapy are summarized in table 1. All of the patients had prior ARVT experience with reverse transcriptase inhibitors tinuation of secondary prophylaxis. Secondary prophylaxis was stopped once the patient had a CD4 (nucleoside analogues), and all of them continued their ARVT regimen until the introduction of PIs.
cell count ú150/mm 3 , an undetectable plasma HIV load, and a negative plasma PCR for CMV. Secondary prophylaxis was planned to During the maintenance period, catheter-related bacteremia involving Enterobacter species and Bacillus cereus was observed;
be reintroduced if CD4 cell counts declined to õ150/mm 3 during follow-up. All patients achieved CD4 cell counts of ú150 cells/mm load of õ200 copies/mL, and a negative qualitative CMV PCR. NOTE. At both time points, all patients had HIV loads of õ200 copies/mL and negative results for qualitative polymerase chain reaction. During follow-up, no new episodes of CMV or new AIDS-defining events occurred. HAART Å highly active antiretroviral therapy, d4T Å stavudine, 3TC Å lamivudine, IDV Å indinavir, RTV Å ritonavir, SQV Å saquinavir.
* 3 months after initiation of treatment with protease inhibitors. Our data differ from those of Jacobson et al. [15] ; however, remain ú100 cells/mm
